Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 9 studies | 26% ± 10% | |
oligodendrocyte precursor cell | 7 studies | 34% ± 14% |
Insufficient scRNA-seq data for expression of RTKN at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 3031.39 | 2628 / 2642 | 100% | 84.58 | 703 / 705 |
kidney | 100% | 4641.36 | 89 / 89 | 99% | 44.18 | 893 / 901 |
skin | 100% | 2018.54 | 1808 / 1809 | 99% | 44.25 | 468 / 472 |
esophagus | 100% | 1403.95 | 1443 / 1445 | 99% | 40.38 | 181 / 183 |
intestine | 100% | 1824.82 | 965 / 966 | 99% | 48.33 | 520 / 527 |
pancreas | 100% | 1785.64 | 328 / 328 | 98% | 33.32 | 175 / 178 |
liver | 100% | 6110.13 | 226 / 226 | 98% | 44.50 | 399 / 406 |
thymus | 100% | 2164.57 | 653 / 653 | 98% | 29.54 | 594 / 605 |
stomach | 100% | 1243.13 | 359 / 359 | 98% | 44.52 | 280 / 286 |
prostate | 100% | 1990.03 | 245 / 245 | 97% | 23.22 | 486 / 502 |
lung | 98% | 1145.27 | 567 / 578 | 98% | 32.13 | 1131 / 1155 |
breast | 95% | 1360.02 | 438 / 459 | 99% | 37.06 | 1102 / 1118 |
uterus | 96% | 904.59 | 163 / 170 | 97% | 34.88 | 445 / 459 |
bladder | 100% | 892.29 | 21 / 21 | 90% | 32.21 | 453 / 504 |
ovary | 85% | 819.08 | 153 / 180 | 100% | 53.22 | 429 / 430 |
adrenal gland | 96% | 810.54 | 247 / 258 | 71% | 15.58 | 163 / 230 |
eye | 0% | 0 | 0 / 0 | 100% | 35.86 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 30.53 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 20.94 | 1 / 1 |
heart | 97% | 1003.02 | 836 / 861 | 0% | 0 | 0 / 0 |
adipose | 93% | 831.70 | 1115 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 78% | 590.94 | 1044 / 1335 | 0% | 0 | 0 / 0 |
spleen | 76% | 437.02 | 183 / 241 | 0% | 0 | 0 / 0 |
muscle | 48% | 282.27 | 382 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 28% | 3.17 | 8 / 29 |
peripheral blood | 18% | 329.59 | 171 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007165 | Biological process | signal transduction |
GO_0006915 | Biological process | apoptotic process |
GO_0007266 | Biological process | Rho protein signal transduction |
GO_0031106 | Biological process | septin ring organization |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0000915 | Biological process | actomyosin contractile ring assembly |
GO_0000281 | Biological process | mitotic cytokinesis |
GO_0005575 | Cellular component | cellular_component |
GO_0005829 | Cellular component | cytosol |
GO_0005826 | Cellular component | actomyosin contractile ring |
GO_0005095 | Molecular function | GTPase inhibitor activity |
GO_0005525 | Molecular function | GTP binding |
GO_0005515 | Molecular function | protein binding |
GO_0031267 | Molecular function | small GTPase binding |
Gene name | RTKN |
Protein name | Rhotekin |
Synonyms | RTKN1 |
Description | FUNCTION: Mediates Rho signaling to activate NF-kappa-B and may confer increased resistance to apoptosis to cells in gastric tumorigenesis. May play a novel role in the organization of septin structures. . |
Accessions | ENST00000640304.2 ENST00000233330.6 [Q9BST9-3] Q9BST9 ENST00000305557.9 [Q9BST9-2] A0A1W2PPZ2 ENST00000272430.10 [Q9BST9-1] |